Smithkline Beecham
Article Abstract:
SmithKline Beecham (SB) saw a rise in operating profit of 15% to 1.24 billion pounds sterling in 1994. There was 580 million pounds of restructuring charges in that year, which included integration of DPS and Sterling. The company increased sales of new products and this helped offset the end of a patent on Tagamet, a SB ulcer treatment, in the US. The company is focusing on managed health care, and has a full pipeline of new products. The company's shares are seen as good value in Mar 1995.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Medeva has cures to bring a recovery
Article Abstract:
Medeva has suffered a drop in its stock price due to concern about possible side effects of its Ionamin obesity treatment, and competition for a product to tackle hyperactivity. The company should benefit from increased sales of Hepagene, and vaccines offer an important growth area for Medeva. Revenue will also be aided by five new drug launches. The company aims to reduce investment needs by buying in drugs. Medeva is also strong enough to develop its own products, as is shown by Hepagene.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Xenova
Article Abstract:
Xenova has two anti-cancer products which are performing well in trials, as well as collaboration agreements with a number of large companies. Both products are in phase ll trials, the first product dealing with medication resistance, while the second product is a potential treatment for brain tumors. Alliances help to reduce the company's cash needs. Xenova's partnership with Eli Lilley could involve an annual 5 million pounds sterling revenue.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The dynamics of the social mix. The tide has turned
- Abstracts: Little commonality in the European market. Flexible annuity brings new risks. The rebate debate goes on
- Abstracts: Legal and General. London and Manchester: treasure trove. Life can be wonderful
- Abstracts: Courtaulds pre-Tencel. Courtaulds acts at last. Tencel or tinsel?